Ipsen’s partner Lexicon presents phase III TELESTAR study data at ECC 2015 (Vienna, Austria) showing that telotristat etiprate reduces the average number of daily bowel movements in patients with carcinoid syndrome not adequately controlled by somatostatin analogues.
This article or press release has no online content. Please download the associated documents for more information.
You are now leaving the Ipsen Group section. If you would like to visit an affiliate section, please click Continue. The information provided on this section may not necessarily be applicable to the Ipsen Group.